Trethera Receives $2 Million National Cancer Institute Grant for Advancement of Clinically Relevant Biomarkers in Phase 1 Trial
Summary
"We are honored to receive this highly competitive SBIR grant that supports additional clinical advancement and compelling opportunities for TRE-515," said Dr. Ken Schultz, principal investigator and Trethera CEO. "The NCI grant follows favorable results announced earlier this year from Tretheras Phase 1a clinical trial in high risk, heavily pretreated patients with solid tumor malignancies. Tim Donahue, Trethera Board member and UCLA Chief of Surgical Oncology, commented, "With this funding, we intend to further showcase the therapeutic promise of disrupting nucleoside salvage pathway activity with TRE-515 as a late line therapy in solid tumors. "The preliminary biomarker data support the underlying TRE-515 mechanism as an on-target dCK inhibitor that expects to positively impact disease progression in patients with solid tumors, stated Dr. Jean DeKernion, Trethera Board member and UCLA Professor Emeritus of Urology. A direct Phase 2 NCI award is incredibly competitive and a significant mark of distinction.A discussion summary from the panel of NCI experts that reviewed Tretheras proposal stated, the drug development plan is state of the artnoted efficacy in stabilizing disease progression in more than one patient in the early phase clinical trialpreliminary studies indicate that this assay can be validateddCK represents an important and novel therapeutic target.TRE-515 is an orally delivered therapeutic engineered to inhibit dCK, the key enzyme in the nucleoside salvage pathway.